TY - JOUR
T1 - Guideline adherence of β-blocker initiating dose and its consequence in hospitalized patients with heart failure with reduced ejection fraction
AU - Zhou, Yiling
AU - Zeng, Yuping
AU - Wang, Si
AU - Li, Nan
AU - Wang, Miye
AU - Mordi, Ify
AU - Ren, Yan
AU - Zhou, Youlian
AU - Zhu, Ye
AU - Tian, Haoming
AU - Sun, Xin
AU - Chen, Xiaoping
AU - An, Zhenmei
AU - Lang, Chim
AU - Li, Sheyu
N1 - SL received grants from the Sichuan Science and Technology Program (Grant Number 2019YFH0150) and the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (Grant Number ZYGD18022 and 20HXFH011), National Natural Science Foundation of China (Grant Number 21534008), and the Chief Scientist Office Project (reference number CGA/19/10). YEZ received grants from National Key Development Plan for Precision Medicine Research (Grant Number 2017YFC0910004), the Sichuan Science and Technology Program (Grant Number 2016JY0151), and National Natural Science Foundation of China (Grant Number 81601012).
PY - 2021/11/16
Y1 - 2021/11/16
N2 - Background: We aim to investigate the guideline adherence of β-blocker (BB) initiating dose in Chinese hospitalized patients with heart failure with reduced ejection fraction (HFrEF) and whether the adherence affected the in-hospital outcomes.Methods: This was a retrospective study of patients hospitalized with HFrEF who had initiated BBs during their hospitalization. We defined adherence to clinical practice guidelines as initiating BB with standard dose and non-adherence to guidelines if otherwise, and examined the association between adherence to guidelines and in-hospital BB-related adverse events. Subgroup analyses based on sex, age, coronary heart disease, and hypertension were performed.Results: Among 1,104 patients with HFrEF initiating BBs during hospitalization (median length of hospitalization, 12 days), 304 (27.5%) patients received BB with non-adherent initiating dose. This non-adherence was related to a higher risk (hazard ratio [95% confidence interval]) of BB dose reduction or withdrawal (1.78 [1.42 to 2.22], P < 0.001), but not significantly associated with risks of profound bradycardia, hypotension, cardiogenic shock requiring intravenous inotropes, and severe bronchospasm requiring intravenous steroid during hospitalization.Conclusion: This study identified that over a fourth of patients had received BBs with an initiating dose that was not adherent to guidelines in Chinese hospitalized patients with HFrEF, and this non-adherence was associated with BB dose reduction or withdrawal during hospitalization.
AB - Background: We aim to investigate the guideline adherence of β-blocker (BB) initiating dose in Chinese hospitalized patients with heart failure with reduced ejection fraction (HFrEF) and whether the adherence affected the in-hospital outcomes.Methods: This was a retrospective study of patients hospitalized with HFrEF who had initiated BBs during their hospitalization. We defined adherence to clinical practice guidelines as initiating BB with standard dose and non-adherence to guidelines if otherwise, and examined the association between adherence to guidelines and in-hospital BB-related adverse events. Subgroup analyses based on sex, age, coronary heart disease, and hypertension were performed.Results: Among 1,104 patients with HFrEF initiating BBs during hospitalization (median length of hospitalization, 12 days), 304 (27.5%) patients received BB with non-adherent initiating dose. This non-adherence was related to a higher risk (hazard ratio [95% confidence interval]) of BB dose reduction or withdrawal (1.78 [1.42 to 2.22], P < 0.001), but not significantly associated with risks of profound bradycardia, hypotension, cardiogenic shock requiring intravenous inotropes, and severe bronchospasm requiring intravenous steroid during hospitalization.Conclusion: This study identified that over a fourth of patients had received BBs with an initiating dose that was not adherent to guidelines in Chinese hospitalized patients with HFrEF, and this non-adherence was associated with BB dose reduction or withdrawal during hospitalization.
KW - adverse events < patient safety
KW - beta blocker
KW - electronic medical records
KW - guideline adherence [MeSH term]
KW - heart failure
KW - heart failure with reduced ejection fraction
KW - hospitalization
KW - inverse probability weighting
UR - http://www.scopus.com/inward/record.url?scp=85120540027&partnerID=8YFLogxK
U2 - 10.3389/fphar.2021.770239
DO - 10.3389/fphar.2021.770239
M3 - Article
C2 - 34899323
SN - 1663-9812
VL - 12
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 770239
ER -